Suven Life Sciences Gets Patents for Neurodegenerative Drug
New Delhi: Biopharmaceutical firm Suven Life Sciences on Tuesday said it has been granted one patent each by the US, Israel and Macau for a drug used in the treatment of neurodegenerative diseases.Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.In a BSE filing, the company said it has been granted "one product patent from Israel, one product patent from Macau and...
Login or Register to read the full article
New Delhi: Biopharmaceutical firm Suven Life Sciences on Tuesday said it has been granted one patent each by the US, Israel and Macau for a drug used in the treatment of neurodegenerative diseases.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it has been granted "one product patent from Israel, one product patent from Macau and one product patent from USA corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases".
Earlier, on May 22, the company had said it has been granted patent by Mexico and Singapore for the same drug.
Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
After the grant, Suven Life Sciences' total count of patents stands 21 in US, 5 in Israel and 4 in Macau.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it has been granted "one product patent from Israel, one product patent from Macau and one product patent from USA corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases".
Earlier, on May 22, the company had said it has been granted patent by Mexico and Singapore for the same drug.
Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
After the grant, Suven Life Sciences' total count of patents stands 21 in US, 5 in Israel and 4 in Macau.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd